+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 62 Actively Recruiting clinical trials

F

Actively Recruiting

Healthy Volunteer

Researchers are evaluating a family-centred approach to prevent cardiovascular diseases CVD among adolescents and their families in Uganda. This 5-year study focuses on reducing risk factors like unhealthy diet and physical inactivity that contribute to CVD and other non-communicable diseases NCDs. The study adapts a proven intervention from Asia to the Ugandan context, aiming to support healthier lifestyle behaviors during the critical adolescence period when habits form that affect adult health. The study includes two groups one receiving the FaCe-D intervention, which involves home visits by Village Health Teams delivering diet, physical activity, and health messaging and a control group receiving standard care with usual health promotion activities. The study is divided into three phases adapting the intervention, implementing it, and evaluating its effectiveness and feasibility in 32 villages. Participants will be involved for at least 12 months, during which researchers will assess changes in cardiovascular health and sleep quality. Evaluations include monitoring behavior changes, health outcomes, and implementation costs. The study also considers adoption and feasibility to understand how well the intervention works in real community settings.

Age: 10Years - 19YearsAll GendersPhase Not Applicable
2 locations
G

Actively Recruiting

Researchers are evaluating whether stopping secondary antibiotic prophylaxis SAP is not worse than continuing SAP in preventing worsening of rheumatic heart disease RHD in children and adolescents. This Phase 3 trial focuses on participants aged 5 to 20 years who have mild RHD and have already received at least two years of SAP. The goal is to see if stopping SAP affects heart disease progression compared to continuing treatment. The study is randomized and controlled with a single masking approach. Participants will be randomly assigned to either stop SAP or continue receiving monthly intramuscular benzathine benzylpenicillin G BPG injections for two years. Dosage is based on weight, with children under 30 kg receiving 600,000 IU and those 30 kg or above receiving 1.2 million IU every 28 days. The control group continues the standard care of monthly BPG injections, while the intervention group receives no prophylaxis for the same period. During the study, participants will be monitored for two years to assess the progression of RHD using echocardiographic evaluations based on the 2023 World Heart Federation criteria. Blinded adjudicators will review heart imaging results to determine disease changes. Researchers will also analyze outcomes for subgroups with either normalized or stable mild RHD and explore differences based on prior prophylaxis routes. The trial spans from enrollment through the end of the 2-year treatment period, with safety and disease progression closely followed.

Age: 5Years - 20YearsAll GendersPhase 3
1 location
D

Actively Recruiting

Researchers are studying the daily use of Rifapentine combined with Isoniazid to prevent tuberculosis in children under 13 years old, including those with and without HIV. This Phase III trial aims to find the appropriate dose of this combination taken once daily for 28 days. The study will include up to 144 children divided into two groups based on HIV status and will take place at multiple locations. Participants will receive the study drugs by oral dispersible tablets, grouped by weight into five categories. Children with HIV will also be assessed for their use of Dolutegravir as part of their antiretroviral therapy. The treatment period lasts 28 days, followed by a 24-week follow-up to monitor safety, tolerability, and drug levels in the blood. Both groups will be closely observed to assess how the drugs are processed in their bodies and any adverse effects. During the study, participants will have blood tests to measure drug concentrations and monitor liver, kidney, and blood cell function. Parent or guardian reports on treatment acceptability and adherence will be collected. Researchers will track adverse events throughout the treatment and follow-up periods. The total participation duration includes the initial 28-day dosing phase and subsequent 24 weeks of monitoring to ensure safety and effectiveness of the regimen.

Age: 0 - 13YearsAll GendersPhase 1Phase 2
11 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are investigating new medicines to prevent Human Immunodeficiency Virus Type 1 HIV-1 infection, focusing on women aged 16 to 30 years who are at risk. The study aims to compare the effectiveness and safety of taking MK-8527 once a month against a standard daily pre-exposure prophylaxis PrEP regimen. This phase 3 trial is designed to evaluate if MK-8527 can better prevent HIV-1 infection and how well participants tolerate this medication. Participants will be randomly assigned to one of two groups. One group will take 11 mg of MK-8527 once monthly and a daily placebo matching the standard PrEP medication. The other group will take the daily standard PrEP drugs Emtricitabinetenofovir disoproxil FTCTDF and a monthly placebo matching MK-8527, both for up to approximately two years. After this period, all participants will receive open-label FTCTDF daily for an additional 28 days. During the study, participants will undergo regular monitoring to track new HIV-1 infections, any adverse events, and reasons for discontinuing the study drug due to side effects. The safety and tolerability of MK-8527 will be assessed over the approximately two-year treatment period. The research team will collect data on these outcomes to understand the benefits and risks of MK-8527 as a preventive option for HIV-1 infection.

Age: 16Years - 30YearsFEMALEPhase 3
30 locations
E

Actively Recruiting

Researchers are evaluating propranolol as a treatment for Kaposi Sarcoma in both children and adults. This open-label, single-arm trial aims to assess the safety and effectiveness of propranolol for this condition. The study is sponsored by the AIDS Malignancy Consortium and focuses on participants with biopsy-confirmed, measurable Kaposi Sarcoma who do not require immediate chemotherapy. Participants will take propranolol twice daily for an initial 12-week period, with dosing based on age children 12 years or younger receive 3 mgkgday divided twice daily, while those older than 12 years take 120 mg twice daily. After 12 weeks, responses will be evaluated participants with a complete response continue treatment for an additional 6 weeks, and those with a partial response continue for 12 more weeks. Throughout the study, participants will be closely monitored for treatment responses and safety. Researchers will assess outcomes such as objective response rates, dose-limiting toxicities, and treatment-emergent adverse events at one year. The study includes evaluations of time to recurrence and progression for both children and adults. Total participation may last up to 24 weeks of treatment with follow-up assessments.

All AgesAll GendersPhase 2
6 locations
G

Actively Recruiting

Researchers are evaluating etavopivat in adolescents and adults with sickle cell disease to see if it can reduce vaso-occlusive crises painful blockages in blood vessels and protect organs from damage. This phase 3 study will also assess whether etavopivat improves exercise tolerance and reduces fatigue compared to a placebo. The trial is randomized, double-blind, and placebo-controlled to ensure unbiased results on the medications effects. Participants will be randomly assigned to receive either oral etavopivat or a matching placebo. The study treatment is taken by mouth, and participants will be followed closely for about 2 years. This includes monitoring during the treatment period and ongoing assessments to evaluate the drugs impact on sickle cell disease symptoms and related health measures. Throughout the study, participants will undergo evaluations such as blood tests to measure hemoglobin and other markers, 6-minute walking tests to assess exercise capacity, and fatigue questionnaires. Researchers will track the number of vaso-occlusive crises requiring medical contact over 52 weeks as the primary outcome. Safety and efficacy will be monitored regularly, with follow-up continuing until the study ends approximately 4 years after enrollment begins.

Age: 12Years +All GendersPhase 3
175 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of inavolisib combined with Phesgo compared to placebo with Phesgo as maintenance treatment after initial therapy in people with untreated HER2-positive advanced breast cancer that has a PIK3CA mutation. This phase III trial focuses on how well the treatments control the disease and their side effects. Participants first receive induction therapy with Phesgo plus taxane-based chemotherapy. Afterward, they receive maintenance therapy with either inavolisib plus Phesgo or placebo plus Phesgo in 21-day cycles. Phesgo is given by subcutaneous injection every 3 weeks, while inavolisib or placebo tablets are taken daily on days 1 to 21 of each cycle. Optional endocrine therapy may also be provided according to standard care. During the study, participants undergo regular assessments including tumor evaluations, heart function tests, laboratory tests, and quality of life questionnaires. Researchers monitor progression-free survival up to about 40 months and overall survival and other outcomes up to approximately 111 months. Participants are followed closely for adverse events and drug levels. The total study duration may extend up to nearly 10 years, with visits scheduled throughout treatment and follow-up periods.

Age: 18Years +All GendersPhase 3
192 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of crizanlizumab, a biological drug given at 5 mgkg, compared to a placebo in adolescents and adults aged 12 years and older who have Sickle Cell Disease and experience frequent vaso-occlusive crises VOCs. This phase III, multicenter, randomized, double-blind study includes patients who may or may not be receiving hydroxyurea or hydroxycarbamide therapy. The study aims to better understand how crizanlizumab impacts the rate and severity of VOCs in this population. Participants will be randomly assigned in a 21 ratio to receive either crizanlizumab or placebo, with both groups continuing standard care. The treatment is given as an intravenous infusion and the study allows patients to continue stable doses of hydroxyurea or hydroxycarbamide if they are already on these therapies. The randomization is stratified by hydroxyureahydroxycarbamide use and geographic region. The study treatment period lasts for one year, during which participants receive regular infusions and monitoring. During the trial, participants will be closely monitored with healthcare assessments to track the number of healthcare professional-managed VOCs, time to first VOC, and other important measures such as duration of VOCs, antibody development to the study drug, and changes in hemoglobin levels. Safety is closely evaluated through recording of adverse events over a two-year period. Participants will have regular visits for treatment and evaluation throughout the study, which is expected to last up to six years including follow-up and completion phases.

Age: 12Years - 100YearsAll GendersPhase 3
36 locations
O

Actively Recruiting

This research aims to provide continued access to study drugs for children and adolescents living with HIV-1 who have completed participation in certain prior clinical studies involving Gilead HIV treatments. The main goals are to allow these participants to keep receiving the study drug they were taking or switch to a specific combination drug called bictegraviremtricitabinetenofovir BFTAF, and to monitor the safety of these treatments. Participants will continue taking the study drugs they used in their parent studies, which may include various combinations of antiretroviral medications such as emtricitabinetenofovir alafenamide FTAF with a third agent, elvitegravircobicistatemtricitabinetenofovir alafenamide ECFTAF, or other combinations involving cobicistat and protease inhibitors. Dosages are adjusted based on the participants weight. Some participants may switch to BFTAF at a dose appropriate for their weight. During the study, participants will be monitored for adverse events and treatment safety over time. Researchers will measure how many eligible participants receive access to the study drugs and track any treatment-emergent side effects. The study may last up to several years, with ongoing assessments to ensure participant well-being and to collect safety data.

Age: 1Month +All GendersPhase 4
15 locations
A

Actively Recruiting

This research aims to evaluate the feasibility, sustainability, and public health impact of a district-based program for secondary prevention of Rheumatic Heart Disease RHD in Uganda. It is a non-randomized study testing the implementation of decentralized RHD preventive services, overseen by the Uganda Ministry of Health and District Health Offices in partnership with a technical quality assurance team. The study uses the RE-AIM framework to measure program reach, effectiveness, adoption, implementation, and maintenance while also estimating cost-effectiveness and budget impact. The study involves the ADUNU program, which integrates echocardiographic screening for RHD in children and young adults through community and facility-based testing. The program also includes registry-based secondary prophylaxis injections of Benzathine penicillin G BPG administered at local health centers HCIII and HCIV in the participating districts. This approach is designed to improve access to care and maintain patients linked to treatment. Participants and healthcare providers residing or working in the involved districts will engage with the program over several years. Researchers will assess the proportion of persons reached, enrolled, retained, and adherent to treatment at multiple time points up to five years. They will also evaluate program adoption and implementation at organizational, provider, and patient levels through surveys and interviews, alongside a cost analysis of the program at three years. The study ensures ongoing monitoring of adherence and outcomes to understand the programs public health impact.

Age: 5Years +All GendersPhase Not Applicable
1 location

1-10 of 62

1